ArticleFrontiers in immunology2026
The molecular mechanism of circRNA_0021727 in inflammation of eosinophilic chronic rhinosinusitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Eosinophilic chronic rhinosinusitis (ECRS) is characterized by severe symptoms and a high recurrence rate, yet its pathogenesis remains unclear and difficult to manage with current treatments. This study aims to investigate the role of circRNA_0021727 in ECRS-related inflammation, as well as the regulatory interactions among circRNA_0021727, miRNA_145_5p, and ADAM12 in ECRS. Methods: Primary nasal epithelial cells (PNECs) were isolated from nasal polyp tissues of 10 ECRS patients and inferior turbinate tissues of 10 nasal septum deviation patients for differential expression analysis. Primary cell cultures were established for overexpression and knockdown of circRNA_0021727 and miRNA_145_5p, which were generated to assess ADAM12 expression. An inflammatory model was induced using IL-13 treatment, and the expression levels of GM-CSF, EOTAXIN, and MUC5AC were measured. Results: In ECRS epithelium, circRNA_0021727 and ADAM12 were upregulated, whereas miRNA_145_5p was downregulated. Overexpression of circRNA_0021727 led to decreased miRNA-145-5p and increased ADAM12 expression, whereas knockdown of circRNA_0021727 had the opposite effect. Similarly, overexpression of miRNA_145_5p resulted in decreased ADAM12 levels, while its knockdown increased ADAM12 expression. After IL-13 treatment, GM-CSF, EOTAXIN, and MUC5AC expression levels were elevated in circRNA_0021727-overexpressing cells and reduced in knockdown cells. Conversely, miRNA_145_5p overexpression decreased these inflammatory markers, while knockdown increased their levels. Conclusion: The circRNA_0021727-miRNA-145-5p-ADAM12 regulatory axis plays a role in ECRS pathogenesis. circRNA_0021727 promotes ECRS-related inflammation, suggesting its potential as a therapeutic target for managing the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.